Skip to main content
Figure 7 | BMC Biotechnology

Figure 7

From: Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability

Figure 7

SRID comparison of recombinant and egg-derived HA proteins and anti-serum against H1 A/California/07/2009. Reference antigens are identified by re-assortant (X-181 or X-179A) and source (CBER or NIBSC), and were diluted to 30 μg/mL based on the concentrations provided in the product circulars. Two licensed H1N1 A/California/07/2009 monovalent vaccines (Novartis [1] and Sanofi Pasteur [2]) were included in this analysis. The A/California/07/2009 rHA lots were diluted to a target of 30 μg/mL based on total protein measurements. Panel A: SRID gel using sheep antiserum obtained from NIBSC generated against egg-derived A/California/07/2009 HA; Panel B: SRID gel using CBER experimental sheep antiserum generated against an E. coli-expressed HA1 domain of A/California/07/2009 HA; Panel C: SRID gel using Protein Sciences Corporation (PSC) experimental rabbit antiserum generated against BEVS-insect cell derived rHA.

Back to article page

BMC Biotechnology

ISSN: 1472-6750

Contact us